Molecular Oncology
Volume 1, Issue 3 , Pages 246-251, December 2007

The MINDACT trial: The first prospective clinical validation of a genomic tool

  • Fatima Cardoso

      Affiliations

    • Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 2 541 30 82; fax: +32 2 538 08 58.
    • ,
  • Martine Piccart-Gebhart

      Affiliations

    • Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium
    • ,
  • Laura Van’t Veer

      Affiliations

    • Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    • ,
  • Emiel Rutgers

      Affiliations

    • Department of Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    • ,
  • on behalf of the TRANSBIG consortium

Received 2 October 2007; received in revised form 11 October 2007; accepted 17 October 2007. published online 08 November 2007.

Abstract 

One of the main challenges in oncology today has become to distinguish accurately between those patients who need adjuvant treatment and those who do not. This, together with the identification of the best type of therapy for the individual patient and the development of drugs targeting specific characteristics of tumour cells, are the goals of treatment tailoring or personalized medicine.

The MINDACT trial (Microarray In Node negative Disease may Avoid ChemoTherapy) was recently launched with the aim of prospectively validating the superior performance of a new prognostic RNA-based tool – the Amsterdam 70-gene profiler MammaPrint™, in order to implement its use in clinical practice later on. This manuscript shortly reviews the rational, design and logistics of MINDACT.

Keywords: MINDACT, MammaPrint™, Genomics, Breast cancer, 70-gene profiler

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1574-7891(07)00077-4

doi:10.1016/j.molonc.2007.10.004

Molecular Oncology
Volume 1, Issue 3 , Pages 246-251, December 2007

Article Tools

* Image Usage & Resolution